Best GLP-1 Providers in Delaware (2026)

See by medication

Looking for a specific GLP-1? Browse Delaware providers by drug.

About GLP-1s in Delaware

Delaware permits telehealth GLP-1 prescriptions. Delaware Medicaid (Diamond State Health Plan) covers GLP-1s primarily for type 2 diabetes.

• •Delaware's adult obesity rate is 33.9%
• •Delaware Medicaid limits GLP-1 coverage to diabetes
• •Compounded semaglutide is available through licensed pharmacies

Top Cities for GLP-1 Treatment in Delaware

Telehealth providers ship to all Delaware addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Delaware GLP-1 clinic directory →

GLP-1 Care Access in Delaware: The Numbers

Delaware has 124 NPI-registered in-person weight-management clinics across 15 cities — 5 with an obesity-medicine taxonomy, 45 endocrinology, and 76 bariatric — alongside 95 telehealth programs that ship to Delaware addresses. The cheapest verified ongoing compounded semaglutide price available to Delaware residents is $79/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Delaware

In Q1 2026, Delaware Medicaid reimbursed approximately $5,035,558 across 10,855 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Delaware cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $215/mo.

For the exact criteria, drug list, and appeal process, read our Delaware Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Delaware

According to CDC data, 33.9% of Delaware adults have obesity (BMI of 30 or higher). This places Delaware at #17 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Delaware residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions